AU2022275935A1 - Methods of treating mitochondria-related disorders - Google Patents
Methods of treating mitochondria-related disorders Download PDFInfo
- Publication number
- AU2022275935A1 AU2022275935A1 AU2022275935A AU2022275935A AU2022275935A1 AU 2022275935 A1 AU2022275935 A1 AU 2022275935A1 AU 2022275935 A AU2022275935 A AU 2022275935A AU 2022275935 A AU2022275935 A AU 2022275935A AU 2022275935 A1 AU2022275935 A1 AU 2022275935A1
- Authority
- AU
- Australia
- Prior art keywords
- subject
- dinitrophenol
- methyl
- hours
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163191321P | 2021-05-20 | 2021-05-20 | |
| US63/191,321 | 2021-05-20 | ||
| US202163222841P | 2021-07-16 | 2021-07-16 | |
| US63/222,841 | 2021-07-16 | ||
| US202263307515P | 2022-02-07 | 2022-02-07 | |
| US63/307,515 | 2022-02-07 | ||
| PCT/US2022/029992 WO2022246039A1 (en) | 2021-05-20 | 2022-05-19 | Methods of treating mitochondria-related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022275935A1 true AU2022275935A1 (en) | 2023-12-07 |
Family
ID=82020295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022275935A Pending AU2022275935A1 (en) | 2021-05-20 | 2022-05-19 | Methods of treating mitochondria-related disorders |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250177353A1 (https=) |
| EP (1) | EP4340829A1 (https=) |
| JP (1) | JP2024521709A (https=) |
| KR (1) | KR20240021827A (https=) |
| AU (1) | AU2022275935A1 (https=) |
| BR (1) | BR112023024146A2 (https=) |
| CA (1) | CA3219548A1 (https=) |
| CL (1) | CL2023003441A1 (https=) |
| GE (1) | GEAP202416398A (https=) |
| IL (1) | IL308669A (https=) |
| JO (1) | JOP20230298A1 (https=) |
| MX (1) | MX2023013688A (https=) |
| TW (1) | TW202313010A (https=) |
| WO (1) | WO2022246039A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023150759A1 (en) * | 2022-02-07 | 2023-08-10 | Rivus Pharmaceuticals, Inc. | Methods of weight loss in a subject with elevated hba1c |
| TW202515545A (zh) * | 2023-08-10 | 2025-04-16 | 大陸商深圳君聖泰生物技術有限公司 | ２，４－二硝苯酚之衍生物以及前藥、以及其組成物以及方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1098641B1 (en) | 1998-07-27 | 2016-04-27 | St. Jude Pharmaceuticals, Inc. | Chemically induced intracellular hyperthermia |
| PT3565806T (pt) | 2017-01-06 | 2022-05-19 | Rivus Pharmaceuticals Inc | Novos derivados de fenilo |
-
2022
- 2022-05-19 WO PCT/US2022/029992 patent/WO2022246039A1/en not_active Ceased
- 2022-05-19 KR KR1020237043901A patent/KR20240021827A/ko active Pending
- 2022-05-19 BR BR112023024146A patent/BR112023024146A2/pt unknown
- 2022-05-19 AU AU2022275935A patent/AU2022275935A1/en active Pending
- 2022-05-19 IL IL308669A patent/IL308669A/en unknown
- 2022-05-19 JP JP2023571818A patent/JP2024521709A/ja active Pending
- 2022-05-19 GE GEAP202416398A patent/GEAP202416398A/en unknown
- 2022-05-19 MX MX2023013688A patent/MX2023013688A/es unknown
- 2022-05-19 US US18/562,560 patent/US20250177353A1/en active Pending
- 2022-05-19 EP EP22729956.7A patent/EP4340829A1/en active Pending
- 2022-05-19 CA CA3219548A patent/CA3219548A1/en active Pending
- 2022-05-20 TW TW111118998A patent/TW202313010A/zh unknown
-
2023
- 2023-11-19 JO JOJO/P/2023/0298A patent/JOP20230298A1/ar unknown
- 2023-11-20 CL CL2023003441A patent/CL2023003441A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4340829A1 (en) | 2024-03-27 |
| KR20240021827A (ko) | 2024-02-19 |
| JP2024521709A (ja) | 2024-06-04 |
| CL2023003441A1 (es) | 2024-05-10 |
| JOP20230298A1 (ar) | 2023-11-19 |
| US20250177353A1 (en) | 2025-06-05 |
| TW202313010A (zh) | 2023-04-01 |
| WO2022246039A1 (en) | 2022-11-24 |
| BR112023024146A2 (pt) | 2024-01-30 |
| CA3219548A1 (en) | 2022-11-24 |
| MX2023013688A (es) | 2024-02-27 |
| GEAP202416398A (en) | 2024-01-25 |
| IL308669A (en) | 2024-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zambrowicz et al. | Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes | |
| TWI769976B (zh) | 治療非酒精性脂肪肝病以及/或脂肪失養症之醫藥組成物 | |
| US20250177353A1 (en) | Methods of treating mitochondria-related disorders | |
| JP2016512564A (ja) | Ｔｒｐｖ２受容体アゴニストを用いる拡張期心機能不全の治療 | |
| US20210283105A1 (en) | Novel regimes of fxr agonists | |
| JP2024523945A (ja) | 血糖値の管理方法ならびに糖尿病及び関連状態の治療 | |
| TW201215392A (en) | Use of ranolazine for treating pulmonary hypertension | |
| Ma et al. | Danqi soft caspule prevents atrial fibrillation by ameliorating left atrial remodeling through inhibiting cardiac fibroblasts differentiation and function | |
| US20250134864A1 (en) | Methods of weight loss and preserving skeletal muscle mass | |
| US20210000792A1 (en) | Methods for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus | |
| Kaul et al. | A prospective, multicentre, single arm clinical study to evaluate the effect of saroglitazar on non high-density lipoprotein cholesterol in patients with diabetic dyslipidemia inadequately controlled with diet, exercise, and statin-the GLIDDER study | |
| CN117881399A (zh) | 治疗粒线体相关病症的方法 | |
| JP2025526746A (ja) | 門脈圧亢進症を伴う肝硬変の治療のための併用療法 | |
| US20250134865A1 (en) | Methods of weight loss in a subject with elevated hba1c | |
| WO2019099509A1 (en) | Use of a p2x7 receptor antagonist to treat an inflammatory disease or disorder | |
| CN118900692A (zh) | HbA1c升高的受试者的体重减轻方法 | |
| CN118922187A (zh) | 体重减轻和保持骨骼肌量的方法 | |
| KR20260055436A (ko) | 심부전 치료용 화합물 azd5462 | |
| TW202500575A (zh) | 具有或不具有體重相關合併症之過重或肥胖成人之治療 | |
| TW202444359A (zh) | 用於向患有肝損傷的患者施用帕妥索汀的組合物和方法 | |
| TW202525272A (zh) | 治療心臟衰竭之方法 | |
| Kim et al. | PP. LB03. 15: SERUM GAMMA-GLUTAMYLTRANSFERASE LEVELS ARE ASSOCIATED WITH CONCOMITANT CARDIOVASCULAR RISK FACTORS IN KOREAN HYPERTENSIVE PATIENTS | |
| Aharon et al. | 452 Novel in vivo imaging of acute chemotherapy-induced vascular toxicity |